摘要
目的 探讨肝癌细胞MGMT表达水平与奥沙利铂敏感性的相关性.方法 采用体外培养SMMC-7721、HuH-7和BEL-7402肝癌细胞株.用RT-PCR法检测MGMT的mRNA表达,Western-blot检测MGMT蛋白水平,MTT法检测奥沙利铂对肝癌细胞的抑制作用,并通过甲基化特异性PCR,检测所有细胞的MGMT甲基化的状态.结果 各肝癌细胞系均可检测到MGMT基因和蛋白的表达,其中HuH-7 MGMT的mRNA以及蛋白水平最高;而BEL-7402细胞MGMT的mRNA以及蛋白水平最低,对比MTT IC50显示奥沙利铂对HuH-7的敏感性最低,对BEL-7402敏感性最高.结论 MGMT基因状态可能影响肝癌细胞对奥沙利铂化疗的敏感性.
Objective To investigate the correlation between the expression of MGMT and the sensitivity of oxaliplatin in hepatocellular carcinoma cells. Methods SMMC-7721, HuH-7, BEL-7402 hepatocellular carcinoma cell lines were cultured in vitro. The expression of MGMT was detected by RT-PCR, the protein level of MGMT was detected by Western-blot, the inhibition of oxaliplatin on hepatocellular carcinoma cells was detected by MTT, and the methylation status of MGMT in all cells was detected by methylation-specific PCR. Results The expression of MGMT gene and protein could be detected in all hepatocellular carcinoma cell lines, and the level of HuH-7 MGMT was the highest, while that of BEL-7402 was the lowest. Compared with MTT IC50, oxaliplatin showed the lowest sensitivity to HuH-7 and the highest sensitivity to BEL-7402. Conclusion MGMT gene status may affect the sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy.
作者
石凤灵
史悦
冯城婷
赵晶
陶敏
袁苏徐
李强
梁容瑞
SHI Feng-ling;SHI Yue;FENG Cheng-ting;ZHAO Jing;TAO Min;YUAN Su-xu;Li Qiang;LIANG Rong-rui(Department of Gastroenterology,Suzhou Dushuhu Public Hospital,Suzhou,Jiangsu,215006,China;Department of Oncology,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,215006,China;Department of Rehabilitation,the First People's Hospital of Changzhou,Changzhou,Jiangsu,213003,China;Department of Radiational Oncology,the First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,215006,China;Department of Lympho-hematology,Jiangxi Cancer Hospital,Nanchang,Jiangxi,330029,China)
出处
《中国血液流变学杂志》
CAS
2019年第2期136-140,共5页
Chinese Journal of Hemorheology
基金
国家自然科学基金资助项目(81402477)
江苏省自然科学基金青年项目(BK20140295)
江苏省政府留学奖学金。
关键词
肝癌
MGMT
奥沙利铂
化疗敏感性
hepatocellular carcinoma
MGMT
oxaliplatin
chemosensitivity
